The oral antivirals for COVID-19 are not for use in residents who have a new oxygen requirement for hypoxia or who have a higher oxygen need for a chronic condition. Paxlovid and Molnupiravir are for treatment of residents with mild to moderate COVID-19 illness at risk for progression to severe illness. These antivirals are not for the treatment of residents with severe or critical COVID-19.
